Quantcast
Last updated on April 23, 2014 at 12:06 EDT

Latest chronic migraine Stories

2014-01-08 08:28:02

SAN MATEO, Calif., Jan. 8, 2014 /PRNewswire/ -- Labrys Biologics Inc., a biotechnology company focused on treatments for migraine, today announced that patients are now being enrolled in two separate Phase 2b clinical studies of LBR-101 (formerly RN-307) as a subcutaneous once-monthly treatment for the prevention of frequent migraines. The first study is enrolling subjects with chronic migraine, who experience at least 15 headache days per month. The second study is enrolling subjects...

2013-12-24 16:20:32

Children's Mercy pain management expert provides perspective on new data highlighting efficacy of cognitive behavioral therapy in the treatment of pediatric migraine KANSAS CITY, Mo., Dec. 24, 2013 /PRNewswire/ -- Psychological therapy plus medication appears to be the most effective treatment strategy for chronic migraine in children, but it may take time for the medical system to widely adopt this approach, says an editorial in the current issue of the Journal of the American...

2013-07-19 08:27:07

First Patient Treated in OPTIMISE Clinical Trial Evaluating Safety, Efficacy of Occipital Nerve Stimulation Using Precision(TM) System NATICK, Mass., July 19, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has launched a clinical trial to determine whether occipital nerve stimulation (ONS) using the Precision(TM) System can safely and effectively treat chronic migraine when used in conjunction with anti-migraine medications. The OPTIMISE trial -- a multi-center,...

2013-06-26 08:31:03

SAN MATEO, Calif., June 26, 2013 /PRNewswire/ -- Labrys Biologics Inc., a biotechnology company focused on treatments for chronic migraine, today announced data from three late-breaking poster presentations demonstrating the pharmacokinetics and safety profile of LBR-101 (formerly RN-307) observed in multiple Phase 1 clinical studies. LBR-101 is a humanized monoclonal antibody that blocks the binding of CGRP to its receptor and is in development for the prevention of chronic migraine....

2013-06-10 08:30:05

CHICAGO, June 10, 2013 /PRNewswire-USNewswire/ -- June has been designated Migraine and Headache Awareness Month. This year's theme is "Unmasking the Mystery of Chronic Headaches." Almost 3.2 million Americans are missing work or school, are not able to perform daily chores, or cannot attend family or social activities because of chronic migraine. Chronic migraine primarily affects women who experience migraine headaches on 15 or more days per month. Although 47% of the adults in the U.S....

2013-05-31 08:22:44

MONTREAL, May 31, 2013 /CNW Telbec/ - June is migraine awareness month(1). It is a great opportunity to remember that this neurological disorder is complex and to distinguish chronic migraine from episodic migraine. Chronic migraine is characterized by 15 headache days or more per month, affects 1,4 to 2,2% of the population, or nearly 370,000 Canadians(2), and is the 19(th) most debilitating disease according to the World Health Organization(3). "One of the main issues is that only 20%...

2013-04-23 08:33:32

TORONTO, April 23, 2013 /CNW/ - If you've ever had a splitting headache, and most of us have, then you know how unbearable the pain can be. Lying down in a dark, quiet room is often all you can bear. Thankfully, headaches like these are seldom for most, but for Canadians suffering with Chronic Migraine, they are far too regular and can make managing life's most common and joyous events a struggle. In fact, a new survey of Canadians with Chronic Migraine shows that more than 60 per...

2013-04-18 16:27:11

SANTIAGO, Chile, April 18, 2013 /PRNewswire/ -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced that the Company will be conducting a meeting with clinical investigators in Santiago, Chile, on April 18th, 2013. The meeting will include presentations about the upcoming Phase II clinical study investigating the use of TI-001, intranasal oxytocin, for the treatment of chronic...

2013-03-18 08:29:07

SAN FRANCISCO, March 18, 2013 /PRNewswire/ -- Labrys Biologics Inc., a company focused on treatments for chronic migraine, today announced key executive appointments to lead the development of RN-307, a Phase 2 ready anti-CGRP monoclonal antibody for the treatment of chronic migraine. Marcelo Bigal, M.D., Ph.D., joins Labrys as chief medical officer, along with Michael Chang, Ph.D., as vice president of project management; Michele Bronson, Ph.D., vice president of regulatory and quality;...

2013-01-03 08:25:20

SAN FRANCISCO, Jan. 3, 2013 /PRNewswire/ -- Labrys Biologics Inc., a company focused on treatments for chronic migraine, today announced the completion of a $31 Million Series A financing from four leading venture capital firms, venBio, Canaan Partners, InterWest Partners, and Sofinnova Ventures. With the close of the financing, Labrys has acquired RN-307 from Pfizer Inc., a Phase 2 ready anti-CGRP humanized monoclonal antibody for the treatment of chronic migraine. In addition, Steven P....